Trial reportBlood2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Trial report in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01122472 (Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line), which is not on this map. Cited by 117 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line
Who cites it
117 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL.Frontiers in immunology · 2026Pooled it
- The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.Blood advances · 2026Trial
- [18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network.European journal of nuclear medicine and molecular imaging · 2023Trial
- Trial
- Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.Haematologica · 2022Trial
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- Quantitative longitudinal photoacoustic imaging of vascular oxygenation for therapy response monitoring in Non-Hodgkin lymphoma.Photoacoustics · 2026Article
- Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis.Current oncology (Toronto, Ont.) · 2026Article
- Improving the predictive value of end-of-treatment PET/ CT in diffuse large B-cell lymphoma.Haematologica · 2026Article
- Comparison of changes in dynamic contrast-enhanced magnetic resonance imaging and flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters from baseline to post-neoadjuvant therapy in predicting pathological response in breast cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- PSMA PET/CT-Derived Indicators and Outcomes After [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Interpretable predictions from whole-body FDG-PET/CT using parameters associated with clinical outcome.Communications medicine · 2026Article
- 2026 Update on the Management of Diffuse Large B-Cell Lymphoma.American journal of hematology · 2026Review
- Multi-view deep learning for automated lymphoma staging fromEJNMMI research · 2026Article
- Prognostic Value of Qualitative Splenic [Cancers · 2026Article
- MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.Frontiers in oncology · 2026Article
- Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.European journal of nuclear medicine and molecular imaging · 2025Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell-like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 >70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.